rs763841075
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PP3_StrongBS1_Supporting
The ENST00000053867.8(GRN):āc.415T>Cā(p.Cys139Arg) variant causes a missense change. The variant allele was found at a frequency of 0.000142 in 1,612,904 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000099 ( 0 hom., cov: 32)
Exomes š: 0.00015 ( 0 hom. )
Consequence
GRN
ENST00000053867.8 missense
ENST00000053867.8 missense
Scores
12
5
2
Clinical Significance
Conservation
PhyloP100: 5.06
Genes affected
GRN (HGNC:4601): (granulin precursor) Granulins are a family of secreted, glycosylated peptides that are cleaved from a single precursor protein with 7.5 repeats of a highly conserved 12-cysteine granulin/epithelin motif. The 88 kDa precursor protein, progranulin, is also called proepithelin and PC cell-derived growth factor. Cleavage of the signal peptide produces mature granulin which can be further cleaved into a variety of active, 6 kDa peptides. These smaller cleavage products are named granulin A, granulin B, granulin C, etc. Epithelins 1 and 2 are synonymous with granulins A and B, respectively. Both the peptides and intact granulin protein regulate cell growth. However, different members of the granulin protein family may act as inhibitors, stimulators, or have dual actions on cell growth. Granulin family members are important in normal development, wound healing, and tumorigenesis. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.988
BS1
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.000146 (214/1461708) while in subpopulation MID AF= 0.00416 (24/5768). AF 95% confidence interval is 0.00287. There are 0 homozygotes in gnomad4_exome. There are 111 alleles in male gnomad4_exome subpopulation. Median coverage is 34. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GRN | NM_002087.4 | c.415T>C | p.Cys139Arg | missense_variant | 5/13 | ENST00000053867.8 | NP_002078.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GRN | ENST00000053867.8 | c.415T>C | p.Cys139Arg | missense_variant | 5/13 | 1 | NM_002087.4 | ENSP00000053867 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000992 AC: 15AN: 151196Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
15
AN:
151196
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000179 AC: 45AN: 251476Hom.: 0 AF XY: 0.000228 AC XY: 31AN XY: 135912
GnomAD3 exomes
AF:
AC:
45
AN:
251476
Hom.:
AF XY:
AC XY:
31
AN XY:
135912
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000146 AC: 214AN: 1461708Hom.: 0 Cov.: 34 AF XY: 0.000153 AC XY: 111AN XY: 727170
GnomAD4 exome
AF:
AC:
214
AN:
1461708
Hom.:
Cov.:
34
AF XY:
AC XY:
111
AN XY:
727170
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000992 AC: 15AN: 151196Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 73754
GnomAD4 genome
AF:
AC:
15
AN:
151196
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
73754
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
22
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 17, 2024 | PP3, PP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 13, 2020 | Reported previously in association with a wide spectrum of later-onset ALS-FTLD neurological phenotypes (Brouwers et al., 2008; Piaceri et al., 2014; Redaelli et al., 2018); Asymptomatic carriers of this variant have been found to have lower serum/plasma PGRN levels compared to controls but not as low as in cases with null variants, suggesting a partial loss of function (Sleegers et al., 2009; Finch et al., 2009; Guven et al., 2019); Published functional studies demonstrate that this variant leads to reduced neurite outgrowth stimulating activity compared to wild type (Wang et al., 2010); This variant is associated with the following publications: (PMID: 32772750, 24503614, 27997711, 19158106, 19288468, 30475763, 18565828, 25352065, 23392204, 26444794, 18314228, 20020531, 23742080, 25575133, 26652843, 27632209, 23684369, 22647257, 20028451, 23724906, 21800185, 31031559) - |
GRN-related frontotemporal lobar degeneration with Tdp43 inclusions;C3539123:Neuronal ceroid lipofuscinosis 11 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 08, 2024 | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 139 of the GRN protein (p.Cys139Arg). This variant is present in population databases (rs763841075, gnomAD 0.04%). This missense change has been observed in individual(s) with frontotemporal dementia or Alzheimer disease (PMID: 21800185, 23724906, 24503614, 27632209, 27997711, 34162492, 34435519). ClinVar contains an entry for this variant (Variation ID: 589965). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GRN protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects GRN function (PMID: 20028451, 22781549, 26652843). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 15, 2021 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 13, 2017 | The p.C139R variant (also known as c.415T>C), located in coding exon 4 of the GRN gene, results from a T to C substitution at nucleotide position 415. The cysteine at codon 139 is replaced by arginine, an amino acid with highly dissimilar properties. This alteration has been detected in several individuals with frontal lobe temporal dementia, progressive late onset dementia, and corticobasal syndrome (Brouwers N et al. Neurology, 2008 Aug;71:656-64; Finch N et al. Brain, 2009 Mar;132:583-91; Bernardi L et al. Neurobiol. Aging, 2009 Nov;30:1825-33; Gómez-Tortosa E et al. Eur. J. Neurol., 2013 Sep;20:1319-24; Bagnoli S et al. Cell. Mol. Neurobiol., 2012 Jan;32:13-6; Rodríguez-Rodríguez E et al. Parkinsonism Relat. Disord., 2013 Aug;19:768-9; Guven G et al. PLoS ONE, 2016 Sep;11:e0162592). In vitro functional studes have shown this variant is likely to impair the physiological processing of the protein and structural modeling predicts this variant has a destabilizing effect on the protein (Brouwers N et al. Neurology, 2008 Aug;71:656-64; Wang J et al. J. Neurochem., 2010 Mar;112:1305-15; Karch CM et al. Neurobiol. Aging, 2016 Feb;38:215.e1-12). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
GRN-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 17, 2024 | The GRN c.415T>C variant is predicted to result in the amino acid substitution p.Cys139Arg. This variant has been reported in multiple unrelated individuals with various neurodegenerative conditions including Alzheimer disease, frontotemporal dementia, semantic dementia, progressive nonfluent aphasia, and corticobasal syndrome (Bernardi et al. 2008. PubMed ID: 18314228; Bagnoli et al. 2011. PubMed ID: 21800185; Antonell et al . 2012. PubMed ID: 22647257; Piaceri et al. 2014. PubMed ID: 24503614; Redaelli et al. 2017. PubMed ID: 27997711; Guven et al. 2016. PubMed ID: 27632209). In one report, this variant was detected in an individual with progressive nonfluent aphasia but was also reported in two unaffected family members age 66 and 42 years of age (Antonell et al. 2012. PubMed ID: 22647257). While mutant GRN protein levels did not differ from non-carrier family members, in an axonal outgrowth assay, the p.Cys139Arg mutated PGRNs did not stimulate neurite outgrowth (Wang et al. 2009. PubMed ID: 20028451). This variant is reported in 0.036% of alleles in individuals of South Asian descent in gnomAD and has been consistently classified as uncertain in ClinVar. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
GRN-related frontotemporal lobar degeneration with Tdp43 inclusions Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
T;T;.;T;T;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T;T;T;T;T;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;.;.;.;.;.;H
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.;.;.;.;.;.
REVEL
Pathogenic
Sift
Pathogenic
D;.;.;.;.;.;.
Sift4G
Pathogenic
D;D;D;D;D;D;.
Polyphen
D;.;.;.;.;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at